Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. director and Senior Vice President, Biological Sciences, Uwe Klein reported multiple acquisitions of the issuer's common stock and stock options on 08/18/2025. He purchased options exercisable into 10,452, 4,935, and 7,621 shares at exercise prices of $2.76, $2.76, and $6.81 respectively, and those options underlie the reported common shares. The Form 4 shows 10,452, 4,935, and 7,621 shares were acquired at reported option prices of $2.76, $2.76, and $6.81, and following transactions Klein directly beneficially owns 23,008 shares. In addition, Klein discloses indirect ownership of 104,525 shares held by the Klein 2024 Revocable Trust (co-trustee), which he disclaims beneficial ownership of except to the extent of pecuniary interest. Vesting schedules apply to the option awards with monthly vesting and IPO-contingent vesting described in footnotes.
Samira Shaikhly, identified as Chief People Officer of Septerna, Inc. (SEPN), acquired a derivative award disclosed on Form 4. The filing reports a grant of a stock option to purchase 30,000 shares of Septerna common stock with an exercise price of $11.70; the transaction date is 08/07/2025 and the Form 4 is signed on 08/11/2025.
The option is owned directly, the instrument lists an expiration date of 08/06/2035, and the grant vests in 1/48th of the shares monthly on each monthly anniversary of August 1, 2025, subject to continuous service. Following the transaction the reporting person beneficially owns 30,000 options.
Septerna, Inc. reporting person Elizabeth Bhatt, President and COO, was granted a stock option to acquire 95,000 shares of common stock with an $11.70 exercise price. The transaction is reported with a transaction date of 08/07/2025 and the option appears as a direct holding following the grant.
The option vests in equal monthly installments equal to 1/48th of the shares beginning August 1, 2025, subject to continued service, and the instrument shows an expiration date of 08/06/2035. The filing documents the grant terms but does not disclose the company’s outstanding share count or any cash paid for the award.
Septerna, Inc. reported a compensatory stock option grant to its Chief Medical Officer, Kim Jae B. The award is a stock option to purchase 55,000 shares of common stock at an exercise price of $11.70 per share. The option grant date is shown as 08/07/2025 and the option expires on 08/06/2035. The option vests in a two-step schedule: 2/48ths of the shares become exercisable on October 1, 2025, with the remaining shares vesting in 46 substantially equal monthly installments thereafter, subject to continuous service. The shares are reported as directly owned following the transaction. This filing documents the terms and vesting timetable of the derivative award to an executive officer.
Septerna, Inc. Form 4 reports that Chief Financial Officer Gil M. Labrucherie acquired a stock option on 08/07/2025 to purchase 37,500 shares of common stock at an exercise price of $11.70 per share. The option is recorded as an acquisition and held directly by the reporting person.
The grant includes a service-based vesting schedule: 6/48th of the option shares vest on February 1, 2026, with the remaining shares vesting in 42 substantially equal monthly installments thereafter, subject to continuous service. The option shows an expiration/related date of 08/06/2035 and 37,500 shares are reported as beneficially owned following the transaction.
Septerna, Inc. (SEPN) reported an equity award to Jeffrey Finer, who serves as Chief Executive Officer and a director. The filing shows a grant of a stock option to purchase 210,000 shares of common stock with an exercise price of $11.70 per share and an expiration date of 08/06/2035. The option vests in equal monthly installments equal to 1/48th of the shares, beginning with the monthly anniversary of August 1, 2025, subject to continuous service.
The reported position after the transaction is direct beneficial ownership of the 210,000 options. This disclosure documents a standard long‑term incentive award for the CEO with a multi‑year vesting schedule and a defined exercise price and expiration.
Septerna, Inc. insider Daniel D. Long, the company's SVP of Drug Discovery, received a grant of stock options allowing him to purchase 30,000 shares of Septerna common stock at an exercise price of $11.70 per share.
The option award was recorded with a transaction date of 08/07/2025, carries an expiration date of 08/06/2035, and vests in monthly installments equal to 1/48th of the total award beginning August 1, 2025, subject to continued service. The filing shows the reporting person holds 30,000 options following the transaction and lists the ownership form as direct.
Septerna, Inc. reporting person Uwe Klein, SVP, Biological Sciences, reported acquisition on Form 4 of 30,000 stock options on 08/07/2025. The options carry an exercise price of $11.70 and relate to 30,000 shares of common stock; they are shown as directly owned. The options are listed as exercisable beginning 08/06/2025 and subject to a vesting schedule where 1/48th of the shares vest in substantially equal monthly installments starting August 1, 2025, contingent on the reporting person's continuous service. The form was signed by attorney-in-fact Ran Xiao on 08/11/2025.
Septerna, Inc. reported a net loss of $46.3 million for the six months ended June 30, 2025, compared with a $30.6 million loss in the prior-year period. Revenue remained minimal at $0.3 million for the six months, generated from Vertex research services. Research and development expenses rose to $41.5 million and general and administrative expenses to $13.8 million, driving total operating expenses of $55.2 million. Cash used in operating activities was $43.6 million for the six months. The company had an accumulated deficit of $164.7 million as of June 30, 2025.
The company reported $189.3 million in cash and cash equivalents and $190.0 million of additional marketable securities (current and non-current) for total cash, cash equivalents and marketable securities of approximately $379.2 million, which management states is expected to fund operations for at least 12 months. Material agreements disclosed include a Collaboration and License Agreement with Novo Nordisk for multiple R&D programs with a $195.0 million upfront payment received in July 2025 and potential milestone and royalty payments, and a Vertex milestone payment realized in August 2025 of $12.5 million.
Septerna, Inc. announced that it released its financial results and business highlights for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1 to this Current Report. The filing states the press release is being furnished (and not "filed") for purposes of the Exchange Act, and the 8-K itself does not include detailed financial statements or metrics. Readers should consult Exhibit 99.1 for the substantive results and disclosures.